Our Pricing

Wegovy After Mounjaro: Complete UK Transition Guide

Switching to Wegovy after Mounjaro is a common transition many UK patients consider when managing their weight loss journey. Whether you're experiencing supply issues with Mounjaro, seeking a different dosing schedule, or exploring alternative GLP-1 receptor agonist options, understanding how to safely transition between these two medications is essential. At Cured Pharmacy, our UK-registered clinical team provides expert guidance on switching from tirzepatide to semaglutide, ensuring continuity of care throughout your weight management programme.

Why Patients Switch to Wegovy After Mounjaro

Many UK patients transition to Wegovy after Mounjaro for several legitimate clinical and practical reasons. Supply chain disruptions have periodically affected Mounjaro availability across the UK, prompting prescribers to recommend Wegovy as a reliable alternative [1]. Both medications are GLP-1 receptor agonists proven effective for weight management, though they contain different active ingredients — tirzepatide in Mounjaro versus semaglutide in Wegovy.

Some patients find Wegovy's once-weekly injection schedule more suitable for their lifestyle, particularly if they experienced gastrointestinal side effects with Mounjaro's dual GIP/GLP-1 mechanism. Clinical trials show Wegovy produces average weight loss of 15-17% of initial body weight over 68 weeks in the STEP programme, whilst Mounjaro demonstrated up to 22.5% weight reduction in SURPASS trials [2]. Individual response varies considerably, and our superintendent pharmacist Tarun Kumar (GPhC 2233073) works with prescribers to determine the most appropriate medication for each patient's circumstances.

Safe Dosing Protocol for Wegovy After Mounjaro

Transitioning to Wegovy after Mounjaro requires careful consideration of your current tirzepatide dose and how it correlates with semaglutide dosing. The MHRA-approved Wegovy dosing schedule begins at 0.25mg weekly, escalating gradually to the maintenance dose of 2.4mg over 16-20 weeks [3]. This titration minimises gastrointestinal side effects and allows your body to adjust to the medication.

If you've been taking Mounjaro 5mg, your prescriber will typically start Wegovy at a lower dose than 2.4mg initially, often beginning at 0.5mg or 1mg weekly depending on how long you've been off tirzepatide. Patients on higher Mounjaro doses (10mg or 15mg) may transition to Wegovy 1.7mg or 2.4mg more quickly, but this decision must be made by your UK-registered prescriber based on your tolerance and clinical response. Never adjust dosing independently — always consult your healthcare provider before making changes.

Recommended Transition Timeline

Most UK clinicians recommend waiting 5-7 days after your last Mounjaro injection before starting Wegovy, allowing tirzepatide to clear your system whilst maintaining some GLP-1 activity [4]. This approach minimises the risk of a gap in appetite control and metabolic benefits. Your prescriber may adjust this timeline based on your individual circumstances, previous side effect profile, and current Mounjaro dose. At Cured Pharmacy, our clinical assessment process ensures your transition is supervised by qualified UK healthcare professionals who understand the nuances of switching between these medications.

Wegovy After Mounjaro: Expected Results and Efficacy

Patients switching to Wegovy after Mounjaro often ask whether they'll maintain their weight loss or continue losing weight. Clinical evidence suggests that continuing GLP-1 therapy, even when switching medications, helps preserve weight loss achievements [5]. However, because Mounjaro contains both GIP and GLP-1 receptor agonists whilst Wegovy contains only GLP-1, some patients may experience different appetite suppression or metabolic effects.

In our experience at Cured Pharmacy, most patients transitioning to Wegovy after Mounjaro maintain their weight loss when the medication is combined with sustainable dietary and lifestyle modifications. Some patients continue to lose weight on Wegovy, particularly if they weren't at the maximum Mounjaro dose previously. The key is consistent medication adherence, proper dose titration under medical supervision, and realistic expectations about individual variation in response.

Managing Side Effects During Transition

Gastrointestinal side effects — nausea, diarrhoea, constipation — are the most common concerns when switching to Wegovy after Mounjaro. Interestingly, some patients who experienced significant nausea on tirzepatide find semaglutide more tolerable, whilst others have the opposite experience [6]. Starting at an appropriate Wegovy dose based on your previous Mounjaro tolerance helps minimise these effects. Eating smaller, more frequent meals, staying well-hydrated, and avoiding high-fat foods can reduce nausea during the transition period. If side effects become severe or persistent, contact your prescriber immediately — dose adjustments may be necessary.

Cost Comparison: Wegovy After Mounjaro in the UK

Pricing is often a significant factor when considering Wegovy after Mounjaro. At Cured Pharmacy, Wegovy is available from £20 offering competitive UK pricing with transparent upfront costs shown before your clinical consultation. We provide all Wegovy doses from the initial 0.25mg through to the maintenance 2.4mg dose, ensuring continuity throughout your titration schedule.

Many UK patients find the cost difference between these medications influences their choice, particularly for long-term weight management. Our pricing includes the medication, UK prescriber consultation, and discreet delivery to your door. New patients can Save £20 on their first order using code Weightlossnew, making the transition to Wegovy after Mounjaro more affordable. Unlike some providers, we never charge hidden consultation fees or subscription costs — you pay only for the medication you need, when you need it.

Clinical Considerations for Wegovy After Mounjaro

Before transitioning to Wegovy after Mounjaro, your UK prescriber will review your medical history, current health status, and response to tirzepatide. Certain contraindications apply to both medications, including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [7]. Your prescriber will also assess kidney function, as GLP-1 medications can affect hydration status, particularly if gastrointestinal side effects occur.

Patients with type 2 diabetes require special consideration when switching between these medications, as both affect blood glucose levels. Your prescriber may need to adjust other diabetes medications, particularly insulin or sulfonylureas, to prevent hypoglycaemia during the transition. Regular blood glucose monitoring is essential during this period. At Cured Pharmacy, our clinical assessment process is conducted by UK-registered prescribers who understand these complexities and ensure safe, appropriate prescribing for every patient.

Drug Interactions and Precautions

Wegovy can slow gastric emptying, potentially affecting the absorption of oral medications [8]. If you take thyroid medication, oral contraceptives, or other time-sensitive drugs, inform your prescriber during your consultation. Timing adjustments may be necessary to maintain therapeutic effectiveness. Additionally, both Mounjaro and Wegovy can increase heart rate slightly in some patients — those with cardiovascular conditions should be monitored appropriately. Our superintendent pharmacist Tarun Kumar ensures all potential interactions are reviewed before dispensing, providing an additional safety check beyond the prescriber consultation.

How to Order Wegovy After Mounjaro from Cured Pharmacy

Ordering Wegovy after Mounjaro from Cured Pharmacy is straightforward and fully compliant with UK regulations. Start by completing our online clinical assessment, which takes under 3 minutes and covers your medical history, current medications, and previous experience with Mounjaro. A UK-registered prescriber reviews your assessment, typically within hours, and determines whether Wegovy is appropriate for your circumstances.

Once approved, your medication is dispensed by our GPhC-registered pharmacy (registration 9012511) and dispatched in 100% discreet packaging. We stock all Wegovy doses from 0.25mg through 2.4mg, ensuring you can progress through the titration schedule without interruption. Next-day delivery is available across the UK, and our clinical team remains available to answer questions throughout your treatment. Remember to use code Weightlossnew for £20 off your first order, making your transition to Wegovy after Mounjaro both clinically sound and cost-effective.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. [accessed 15 August 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
6. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
7. Electronic Medicines Compendium. (2023). Mounjaro 5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. [accessed 15 August 2026]
8. Smits, M. M., & Van Raalte, D. H. (2021). Safety of semaglutide. Frontiers in Endocrinology, 12, 645563. [accessed 15 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.